Antti Mustonen

Antti Mustonen

Affiliated to Research
Visiting address: Avd försäkringsmedicin, Karolinska Institutet, 17177 Stockholm
Postal address: K8 Klinisk neurovetenskap, K8 Fm Mittendorfer-Rutz, 171 77 Stockholm
Part of:

About me

  • I am an Assistant Professor of Psychiatry at Tampere University, Finland, and Chief Physician in the Addiction psychiatry unit at Seinäjoki Central Hospital, Finland. At the Karolinska Institute, I am an affiliated researcher in the Department of Clinical Neuroscience, working in Professor Ellenor Mittendorfer-Rutz’s MENTE group. I collaborate closely with Senior Researcher Heidi Taipale on our joint research projects.

Research

  • My research focuses on the relationship between youth cannabis use and mental health outcomes, particularly how early cannabis exposure influences the development and prognosis of psychiatric disorders, as well as the identification of effective treatments for such conditions.

    I co-lead projects examining the long-term outcomes and real-world effectiveness of treatments for severe mental and substance use disorders, with a special emphasis on cannabis-related conditions. These studies leverage national health registers and large birth cohort data to explore clinical trajectories and treatment outcomes in real-world settings.

    I collaborate with people with lived experience of mental illness and substance use. By integrating clinical evidence with experiential knowledge and drawing on international, multidisciplinary collaboration, my goal is to inform treatment strategies that improve outcomes, reduce harm, and enhance quality of life for individuals living with severe mental disorders and substance use disorders.

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2025 - 31 December 2027
    Cannabis use is increasing worldwide and also certain European countries plan to legalize or decriminalize cannabis. This will further increase use rates and also result into higher number of people with cannabis use disorder. Cannabis use in persons with severe mental disorders, namely schizophrenia-spectrum disorders, bipolar disorders and major depressive disorder, has been reported to adversely impact on illness course and associate with non-adherence to treatments. However, impacts of cannabis use disorder on long-term treatment outcomes in severe mental disorders are not known.  The overall aim of this project is to investigate long-term treatment pathways and outcomes of patients with severe mental disorder and comorbid cannabis use disorder, to help in designing optimal health care for these patients. We aim to investigate healthcare service and medication use and work disability during first five years of illness, compared to patients with severe mental disorder without cannabis use disorder. We will also investigate risk of mortality and effectiveness of medications associated with decreased risk of illness relapse, and mortality. Finally, we will develop a prediction model for adverse clinical outcomes to help clinical practice to inform which patients are at the highest risk and in need of enhanced monitoring and effective interventions. Further, we will investigate whether treatment can be tailored based on the predicted risk level.

News from KI

Events from KI